Drugs / Aficamten
Aficamten
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Myqorzo | — | 2026-02-12 | europa.eu ↗ |
| Approved | US (FDA) | MYQORZO | — | 2025-12-19 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05924815 | May → Nov 2023 | — | Cytokinetics | Completed | No outcome recorded |
| Phase 1 | NCT04783766 | Apr → Aug 2021 | hypertrophic cardiomyopathy | Corxel Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03767855 | Dec 2018 → Jan 2020 | hypertrophic cardiomyopathy | Cytokinetics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04219826 | Jan 2020 → Feb 2023 | hypertrophic cardiomyopathy | Cytokinetics | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06412666 | May 2024 → Jan 2030 expected | hypertrophic cardiomyopathy | Cytokinetics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04848506 | May 2021 → Mar 2028 expected | hypertrophic cardiomyopathy | Cytokinetics | Enrolling by invitation | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07023341 | Jun 2025 → Aug 2026 overdue | hypertrophic cardiomyopathy | Bayer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06116968 | Nov 2023 → Oct 2025 | hypertrophic cardiomyopathy | Corxel Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT06081894 | Aug 2023 → Jun 2026 overdue | hypertrophic cardiomyopathy | Cytokinetics | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05767346 | Jun 2023 → Feb 2025 | hypertrophic cardiomyopathy | Cytokinetics | Completed | No outcome recorded |
| Phase 3 | NCT05186818 | Feb 2022 → Nov 2023 | hypertrophic cardiomyopathy | Cytokinetics | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07600177 | May → Dec 2026 expected | hypertrophic cardiomyopathy | Oregon Health and Science University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aficamten | “This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274) in healthy adults identified a pharmacologically active range of doses and exposures.” PMID 36061336 ↗ Aug 20229“The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM.” NCT07023341 ↗ |
| Known as | BAY3723113 | “The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM.” NCT07023341 ↗ |
| Known as | CK-3773274 | “This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274) in healthy adults identified a pharmacologically active range of doses and exposures.” PMID 36061336 ↗ Aug 20224“A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten [CK-3773274] in Hypertrophic Cardiomyopathy” NCT04848506 ↗ “Aficamten (CK-3773274) tablets administered orally” NCT05767346 ↗ |
| Action | Inhibit | “Cardiac Myosin Inhibitor Aficamten” PMID 36061336 ↗ Aug 2022 |
| Modality | Small molecule | — CHEMBL4847050 ↗ |
| Route | Oral | “CK-3773274 tablets administered orally once daily” NCT04219826 ↗ |